The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche
Research Funding - Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Wenzhao Zhong
Honoraria - AstraZeneca; Lilly; Pfizer; Roche; Sanofi
 
Qun Wang
No Relationships to Disclose
 
Weimin Mao
No Relationships to Disclose
 
Song-Tao Xu
No Relationships to Disclose
 
Lin Wu
No Relationships to Disclose
 
Chun Chen
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Lin Xu
No Relationships to Disclose
 
Jun Wang
No Relationships to Disclose
 
Xiao-Fei Li
No Relationships to Disclose
 
Jian Li
No Relationships to Disclose
 
Cheng Huang
No Relationships to Disclose
 
Zhidong Liu
No Relationships to Disclose
 
Shun Xu
No Relationships to Disclose
 
Jin-Ji Yang
No Relationships to Disclose
 
Hong-Hong Yan
No Relationships to Disclose
 
Xue-Ning Yang
No Relationships to Disclose
 
Si-yang Liu
No Relationships to Disclose
 
Qing Zhou
Honoraria - AstraZeneca; Roche